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The effects of angiotensin converting enzyme inhibitors 
(ACEI) on human N-Acetyl-Seryl-Aspartyl-Lysyl-Proline 
(AcSDKP) levels:  Rationale and Background Information 
 
SUMMARY 
Tuberculous pericardial effusion is complicated by pericardial fibrosis which manifests with the 
clinical feature of constrictive pericarditis in 4.4 to 7.8% and constriction in at least 50% of 
cases (Mayosi et al., 2014). N-acetyl-seryl-aspartyl-lysylproline (AcSDKP) is a ubiquitous 
tetrapeptide with important antifibrotic properties that has recently been shown to be low in 
tuberculous pericardial effusion(Ntsekhe et al., 2012a). It has been postulated that the low 
levels of Ac-SDKP in tuberculous pericarditis may be the pathophysiological basis of the high 
rate of constriction. Angiotensin converting enzyme inhibitors (ACEI) increase AcSDKP levels in 
animal models with antifibrotic effects. ACEIs are therefore, candidate drugs for prevention of 
fibrosis in tuberculous pericarditis, if they can be shown to increase the levels of AcSDKP in 
human tissues. 
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Background 
The genus Mycobacterium contains more than 140 species (Van Ingen, 2013) which are 
separated in three major groups, that is, M. tuberculosis, M. leprae, and mycobacteria other  
than M.tuberculosis and M. leprae, collectively referred to as non-tuberculous mycobacteria. 
Mycobacterium tuberculosis is an obligate human pathogen and the causative agent of 
tuberculosis (TB), which remains one of the leading global public health problems. According to 
the world health organisation’s 2014 global report on tuberculosis, Tuberculosis (TB) still 
remains a major global health problem, responsible for ill-health among millions of people each 
year. TB ranks as the second leading cause of death from an infectious disease worldwide, 
after the human immunodeficiency virus (HIV).The latest estimates included in the report state 
that there were 9.0 million new TB cases in 2013 and 1.5 million TB deaths (1.1 million among 
HIV-negative people and 0.4 million among HIV-positive people).The totals included are higher 
than those included in the 2013 global TB report, primarily because of upward revisions to 
estimates of the number of TB cases and deaths in Nigeria following the finalization of results 
from the country’s first-ever national TB prevalence survey which was completed in 2012. 
 
Anatomy of the Pericardium 
The pericardium is a double-walled fibroserous sac that encloses the heart and the roots of the 
great vessels. It consists of the fibrous pericardium which is bound to the central tendon of the 
diaphragm by the pericardiacophrenic ligament. Anteriorly the fibrous pericardium is bound to 
the sternum by the sternopericardium ligament and posteriorly, it’s bound by loose connective 
tissue structures in the posterior mediastinum. This arrangement ensures that the heart is 
tethered in place inside the fibrinous sac. The internal surface of the fibrinous pericardium is 
lined with a serous membrane which is referred to as the parietal layer of serous pericardium. It 
is this serous layer that is then reflected onto the heart at the great vessels (aorta, pulmonary 
trunk, and veins and venae cavae) and is referred to as the visceral pericardium. The 
pericardial cavity is the potential space between the opposing layers of the parietal and visceral 
layers of the serous pericardium. This space normally contains about 10-20ml of fluid which is 
there to enable the heart to move and beat in a frictionless environment. The parietal layer of 
the serous pericardium fuses to the internal surface of the fibrous pericardium.  
 
The visceral layer of the pericardium forms the epicardium, which is the external layer of the 
heart wall and reflects from the heart and great vessels to become continuous with the parietal 
layer of serous pericardium whereby: 
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a)  The aorta and pulmonary trunk leave the heart; a digit can be inserted into the 
transverse pericardial sinus located posterior to these large vessels and anterior to the 
superior vena cava. 
b)  The superior vena cava, the inferior vena cava and the pulmonary veins enter the heart; 
these great vessels are partly covered by the serous pericardium which forms the 
oblique pericardial sinus.  
 
The arterial supply of the pericardium is mainly from a slender branch of the internal thoracic 
artery, the pericardiacophrenic artery, which often accompanies or at least parallels the phrenic 
nerve to the diaphragm. Smaller contributions of blood arise from the: 
a)  Musculophrenic artery-a terminal branch of the internal thoracic artery 
b) Bronchial, esophageal and superior phrenic arteries-branches of the thoracic aorta 
c) Coronary arteries (visceral layer of serous pericardium only).  
 
The venous drainage of the pericardium is from the: 
a) Pericardiacophrenic veins, tributaries of the brachiocephalic (or internal thoracic) veins 
b) Variable tributaries of the azygous venous system.  
 
The nerve supply of the pericardium is from the  
a)  Phrenic nerves (C3-C5)-primary source of sensory fibres. Pain sensations conveyed by 
the phrenic nerves are commonly referred to the skin of the ipsilateral supraclavicular 
region (top of shoulder on the same side)  
b)  Vagus nerve-function of which is uncertain 
c)  Sympathetic trunks-vasomotor 
 
 
Tuberculous Pericarditis 
The cardiac manifestations of tuberculosis include the development of tuberculosis pericarditis. 
According to the heart of Soweto study, Tuberculosis (TB) pericarditis was the second most 
common cause of cardiovascular morbidity and mortality after HIV-associated cardiomyopathy 
(Sliwa et al., 2012). It has been established that TB pericarditis can present in one of three 
forms, namely; pericardial effusions, effusive-constrictive pericarditis and constrictive 
pericarditis. With regards to the pathogenesis of TB pericarditis, the pericardium can get 
infected as a result of haematogenous spread from primary TB infection or retrograde lymphatic 
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spread of Mycobacterium TB from lymph nodes located in the tracheal, peribronchial and 
mediastinal regions, thereafter protein antigens form the TB bacillus induce delayed (type IV) 
hypersensitivity responses which in-turn stimulate the release of  lymphocytes which in turn 
release lymphokines leading to the activation of macrophages and subsequent granuloma 
formation.  
 
There have been 4 pathological phases which have been identified in TB pericarditis, namely: 
 
a) Fibrinous exudation with a polymorphonuclear leukocytosis, associated with 
relatively abundant mycobacteria, and early granuloma formation with loose 
organization of macrophages and T cell 
 
b) Serosanguineous effusion with a predominant lymphocytic exudate with monocytes 
and foam cells 
 
c) Absorption of effusion with organization of granulomatous caseation and pericardial 
thickening caused by fibrin, collagenosis, and ultimately, fibrosis 
 
d) Constrictive scarring: whereby the fibrosing visceral and parietal pericardium encase 
the heart in a fibrocalcific skin which impedes filling during diastole leading to the 
syndrome constrictive pericarditis. 
 
Diagnosis 
The symptoms and signs are usually non-specific and vague in TB pericarditis; a chest 
radiograph reveals an enlarged cardiac shadow in over 90% of cases and may reveal features 
of active tuberculosis and the presence or absence of pleural effusions. The 
Electrocardiographic (ECG) changes are virtually abnormal and range from non-specific ST-T 
changes, PR segment depression and ST elevation (in acute pericarditis), microvoltage 
(complexes<5mm in limb leads&<10mm in precordial leads) in pericardial effusions.  
 
Atrial fibrillation has been shown to have occurred in 25% of patients with tuberculous 
pericardial effusions (Syed et al., 2012).The echocardiogram may reveal features suggestive of 
an exudative effusion but not specific for a tuberculous aetiology namely: frond like projections 
and thick ‘porridge-like’ fluid. Imaging in the form of CT/MRI scan of the chest where available 
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may be of assistance in diagnosing pericardial effusions and features suggestive of tuberculous 
effusion include a pericardial effusion and thickening >3mm associated with typical mediastinal 
and tracheobronchial lymphadenopathy (>10mm, hypodense centres, matting) with sparing of 
the hilar nodes. 
 
Pericardiocentesis 
Pericardiocentesis is mandatory for patients who have clinical features of cardiac tamponade -
not only is it a therapeutic intervention, but it also assists in diagnosis. Diagnostic 
pericardiocentesis should be considered in all patients with suspected TB pericarditis. 
Pericardial fluid should be sent for biochemical tests to distinguish between exudate and 
transudate, cytology, white cell count and culture-which still remains the goal standard for 
diagnosis of tuberculosis, however tuberculous pericardial fluid has been shown to be 
paucibacillary with estimated culture and microscope smear based diagnostic accuracy of 
approximately 50% and 5% respectively and the ‘turn-around’ time of 4-6weeks is associated 
with a delay in diagnosis(Theron et al., 2014) (Reuter, Burgess, van Vuuren, & Doubell, 2006).  
 
The Xpert MTB/Rif which is a quantitative polymerase chain reaction (PCR) and can assist in 
the rapid diagnosis of Mycobacterium Tuberculosis and rifampicin resistance, has been 
endorsed by the WHO for the diagnosis of pulmonary TB using sputum samples and validation 
studies using culture positive sputum samples from pulmonary TB patients showed a pooled 
sensitivity of 98% and 68% in smear-positive and smear negative cases (“Cochrane database 
for sytematic reviews,” 2013). Indirect tests such as:  
 
a) Adenosine deaminase (ADA) level which is the current available surrogate marker that 
suggests MTB infection, according to the South African national health laboratory 
services reference ranges for normal ADA levels are : 0-15U/L for serum,0-30U/L for 
pleural fluid and 0-9U/L for cerebrospinal fluid. Locally available, yet unvalidated data 
regarding ADA measurements in pericardial fluid suggests an ADA cut-off value of 40 
U/L resulted in a test sensitivity, specificity, positive predictive value, negative predictive 
value and diagnostic efficiency of 84%, 80%, 91%, 66%, and 83%, respectively(Reuter, 
H, Burgess, LJ, Carstens, ME, Doubell, 2005) 
 
b)  Unstimulated Interferon Gamma assay-Pandie et al assessed the diagnostic utility of 
Xpert MTB/RIF test compared to ADA and unstimulated interferon gamma assay in the 
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diagnosis of Tuberculous pericardial fluid in a population with a high disease burden of 
TB and he was able to show that unstimulated interferon gamma offered superior 
accuracy for the diagnosis of microbiologically confirmed TBP compared to the new 
Xpert MTB/RIF test and the established ADA assay. Unstimulated interferon gamma 
assay maybe the optimal first line test for the diagnosis of TB pericarditis (Pandie et al., 
2014) 
 
Management 
Antituberculosis chemotherapy increases survival dramatically in tuberculous pericarditis. In the 
pre-antibiotic era, mortality was 80% to 90% (Harvey & Whitehill, 1937). A regimen consisting of 
rifampicin, isoniazid, pyrazinamide, and ethambutol for at least 2 months, followed by isoniazid 
and rifampicin (total of 6 months of therapy) has been shown to be highly effective in treating 
patients with extrapulmonary TB (Cohn, DL, Catlin, BJ, Peterson, KL, Judson, FN, Sbarbaro, 
1990). Treatment for 9 months or longer gives no better results and has the disadvantages of 
increased cost and poor compliance. The role of corticosteroids in the management of TB 
pericarditis has been addressed by the Investigation of the Management of TB pericarditis in 
Africa (IMPI) - a multicentred randomized controlled trial which evaluated the effects of 
adjunctive glucocorticoid therapy and mycobacterium indicus pranii immunotherapy in patients 
with tuberculous pericarditis (Mayosi et al., 2014).  There was no significant difference in the 
primary outcome between patients who received prednisolone and those who received 
placebo. 
 
The treatment of tuberculous pericardial constriction involves the use of standard 
antituberculosis drugs for 6 months and pericardiectomy for persistent constriction in the face of 
drug therapy. Mutyaba et al, investigated the causes of constrictive pericarditis, outcomes after 
pericardiectomy, and predictors of mortality in Cape Town, South Africa, during a 22-year period 
of high HIV/AIDS prevalence. He found that tuberculosis is the main cause of constrictive 
pericarditis in South Africa, and that despite its efficacy at relieving the symptoms of heart 
failure, pericardiectomy was associated with high perioperative mortality that was not influenced 
by HIV status and that the New York Heart Association functional(class IV) and hyponatremia 
where predictors for early mortality after pericardiectomy (Mutyaba et al., 2014) 
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Angiotensin Converting Enyme inhibitors (ACEI) and N-
Acetyl-Seryl Aspartyl-Lysyl-Proline (AcSDKP) 
It is known that somatic angiotensin converting enzyme (ACE) consists of two homologous 
catalytically active domains (designated N- and C- domains) that share high overall sequence 
identity and structural topology (Bernstein et al., 2011; Wei, Alhenc-Gelas, Corvol, & Clauser, 
1991). Despite the high degree of similarity between domains, each domain displays 
differences in substrate processing and inhibitor binding abilities. Bradykinin is hydrolyzed at 
approximately the same rate by both these catalytic sites (Bernstein et al., 2011; Wei et al., 
1991). ACE has a range of substrates, including N-acetylseryl-aspartyl-lysyl-proline (AcSDKP). 
AcSDKP is cleared almost exclusively by ACE and specifically by the N-domain active site of 
this enzyme (Rousseau, Michaud, Chauvet, Lenfant, & Corvol, 1995).  The details of the 
synthetic pathways of endogenous AcSDKP still remain unclear but the information available 
strongly suggests that thymosin β4 (Tβ4) is responsible. Thymosin β4 (Tβ4), which is a  
precursor to AcSDKP, is degraded by prolyl oligopeptidase, a ubiquitously distributed 43-amino-
acid (4,9kDa),that was originally identified as an intracellular peptide, which can sequester G-
actin and regulate its polymerization  (Grillon et al., 1990).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Thymosin β4, a G-actin binding peptide, is cleaved by POP and subsequently its N-terminal tetrapeptide, 
AcSDKP, is synthesized. AcSDKP is hydrolyzed and degraded by ACE. ACE-I may suppress miR-324-
3p, which may inhibit protein expression of POP. Therefore, the mechanisms underlying the increased 
levels of AcSDKP by ACE-I may include both the suppression of degradation pathway and the induction 
of synthesis pathway of AcSDKP 
FIGURE 1:  Synthesis and metabolism of AcSDKP 
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AcSDKP is a tetrapeptide that was originally isolated from fetal calf bone marrow and has 
emerged as an antifibrotic molecule. AcSDKP was originally identified as a hematopoietic stem 
cell regulator and inhibits cell cycle progression stimulated by serum derived or platelet-derived 
growth factor β in human mesangial cells by inhibiting the degradation of p53,p27,and p21 
(Kanasaki et al., 2006). AcSDKP further inhibits apoptosis induced by cytotoxic stresses, 
including chemotherapy (Bogden et al., 1991; Grillon et al., 1993), radiation (Deeg et al., 1997; 
Watanabe et al., 1996), high temperature (P. Wierenga, Brenner, & Konings, 1998; P. K. 
Wierenga, Setroikromo, Vellenga, & Kampinga, 2000; P. Wierenga & Konings, 1994), and 
photofrin -II-mediated phototherapy (Coutton, Guigon, Bohbot, Ferrani, & Oberling, 1994). 
Increased apoptosis is associated with tissue fibrosis and its inhibition has been linked to the 
restoration of fibrosis in several organs (Coward, Saini, & Jenkins, 2010; Dooley, Harvey, & 
Thomas, 2011; Gieling, Burt, & Mann, 2008; Rodriguez-Iturbe & Garcia Garcia, 2010). 
Inflammation is also associated with tissue fibrosis (Coward et al., 2010; Dooley et al., 2011; 
Gieling et al., 2008; Rodriguez-Iturbe & Garcia Garcia, 2010).  AcSDKP mediates its antifibrotic 
effects by blunting the effects of TGFβ signalling through down regulation of the TGFβ/small 
mothers-against decaplentaplegic (Smad 2) and signal-regulated kinase (ERK 1/2) pathways  
(Border & Noble, 1994; Kanasaki, Koya, Sugimoto, & Isono, 2003; Miyazo, 2000; Pokharel et 
al., 2002). Effects are mediated by galectin-3 (Liu et al., 2009; Ntsekhe et al., 2012b), a TGFβ 
releasing macrophage recruiting and cardiac dysfunction molecule, are known to be blunted by 
this mechanism. AcSDKP reverses inflammation and fibrosis in rats with heart failure after 
myocardial infarction(Yang et al., 2004).The plasma level of AcSDKP in humans has been 
shown to increase by fivefold after acute administration of the ACE-inhibitor Captopril (Azizi et 
al., 1996). 
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Once TGF-β binds to TGF-β receptors on the cell membrane, the TGF-β and TGF-β-receptor 
interaction induces phosphorylation of receptor-regulated(R)-Smads. Phosphorylated R Smads 
interact with the common (co)-Smad in the cytoplasm. These Smad heterodimers in the nucleus 
then bind to the genomic promoter region of DNA, which is called the Smad-binding element 
(SBE). AcSDKP may induce Smad7 gene expression, protein stabilization, or translocation from 
the nucleus of cells to the cytoplasm as well as inhibit phosphorylation of R-Smads by TGF-β 
receptors. However, detailed mechanisms are not yet known. 
 
FIGURE 2:  AcSDKP is an anti-TGF-β/Smad peptide 
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Conclusion 
The incidence of TB pericarditis in sub-Saharan Africa continues to increase as the result of the 
human immunodeficiency virus (HIV) epidemic (Cegielski, Lallinger, Ramaiya, Mtulia, & 
Mbanga, 1990). Constrictive pericarditis is one of the most devastating complications of TB 
pericarditis occurring in 4-8% of patients despite prompt antituberculous treatment and 
corticosteroids, and is associated with significant morbidity and mortality (Mutyaba et al., 2014). 
TB pericarditis is associated with decreased levels of  pericardial AcSDKP (Ntsekhe et al., 
2012b); ACE-i via their ability to elevate AcSDKP levels are therefore candidates for the 
treatment of tuberculous pericarditis to prevent fibrotic constriction which would greatly improve 
the mortality and enable clinicians to improve the quality of life of the affected patients with 
pharmacological agents which are cheap, easily available and thus abolish the need for 
pericardiectomy. 
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Abstract  
Background: Tuberculous pericardial effusion is a pro-fibrotic condition that is complicated by 
constrictive pericarditis in 4-8% of cases. N-acetyl-seryl-aspartyl-lysylproline (Ac-SDKP) is a 
ubiquitous tetrapeptide with antifibrotic properties that is low in tuberculous pericardial effusion, 
thus providing a potential mechanism for the heightened fibrotic state. Angiotensin converting 
enzyme inhibitors (ACEI), which increase Ac-SDKP levels with antifibrotic effects in animal 
models, are candidate drugs for preventing constrictive pericarditis if they can be shown to 
have similar effects on AcSDKP and fibrosis in human tissues. 
Objective: To systematically review the effects of ACEIs on Ac-SDKP levels in human tissues. 
Methods: We searched five electronic databases (1996-2014) and conference abstracts with 
no language restrictions. Two reviewers independently selected studies, extracted data and 
assessed methodological quality. The protocol was registered in PROSPERO.  
Results: Four studies with a total of 206 participants met the inclusion criteria. Three studies 
(106 participants) assessed the change in plasma levels of AcSDKP following ACEI 
administration in healthy humans. The administration of an ACEI was associated with an 
increase in AcSDKP levels (mean difference (MD), 5.07 pmol/ml (95% confidence intervals (CI) 
0.64 to 9.51 pmol/ml)). Two studies with 100 participants further assessed the change in 
AcSDKP level in humans with renal failure using ACEI. Administration of an ACEI was 
associated with a significant increase in AcSDKP levels (MD, 8.94 pmol/ml; 95% CI 2.55 to 
15.33; I2 = 44%). 
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Conclusion: ACEI increased AcSDKP levels in human plasma.  These findings provide the 
rationale for the testing of the impact of ACEI in on AcSDKP levels and fibrosis in tuberculous 
pericarditis. 
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Introduction 
The incidence of tuberculous (TB) pericarditis in sub-Saharan Africa is increasing as the result 
of the human immunodeficiency virus (HIV) epidemic (1)(2). TB pericarditis caused by 
Mycobacterium tuberculosis is found in 1% of all autopsied cases of TB and in 1-2% of 
instances of pulmonary TB (3). It is the most common cause of pericarditis in Africa and other 
developing countries in which TB remains a major public health problem (3). Constrictive 
pericarditis is one of the most devastating complications of TB pericarditis occurring in 4-8% of 
cases, despite prompt antituberculosis treatment and corticosteroids (4). The treatment of TB 
pericardial constriction involves the use of standard antituberculosis drugs for 6 months and 
pericardiectomy for persistent constriction in the face of drug therapy.  
 
Mutyaba and others investigated the causes of constrictive pericarditis, outcomes after 
pericardiectomy, and predictors of mortality in Cape Town, South Africa, during a 22-year period 
of high HIV/AIDS prevalence. They found that TB is the main cause of constrictive pericarditis 
in South Africa, and that despite its efficacy at relieving the symptoms of heart failure, 
pericardiectomy was associated with high perioperative mortality of 16% that was not 
influenced by HIV status. New York Heart Association Functional Class IV and hyponatremia 
were predictors of early mortality after pericardiectomy (5).  
 
TB pericarditis is associated with decreased levels of the anti-fibrotic agent N-acetylseryl-
aspartyl-lysyl-proline (AcSDKP) levels (6), whereas ACEIs are known to increase AcSDKP 
levels in rodent tissues (7).  AcSDKP is a potent antifibrotic agent and a negative regulator of 
hematopoietic stem cell differentiation. If ACEIs increase AcSDKP levels in human tissues, then 
they would be candidate drugs for use in TB pericarditis to prevent fibrosis and constriction 
(8)(9)(10)(11).  We have conducted a systematic review of the literature to determine whether 
ACEI increase AcSDKP levels in human tissues. 
Methods 
These methods are based on our protocol which was registered in Prospero (12).  
 
Elligibility Criteria  
Types of participants    
Only studies incorporating human participants will be considered. 
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Types of interventions 
Interventions must include any ACE-I, whether alone or as part of other interventions.  
Types of outcome measures 
Effects of ACE-I on AcSDKP levels in body tissues.   
Types of comparison or control interventions 
Any placebo 
Primary outcomes 
Change in AcSDKP levels as detected by standardised laboratory assays / protocols following 
ACE-i administration in humans. 
Secondary outcome 
Effect of changes in AcSDKP level on fibrotic diseases. 
 
 
Search Strategy 
Two authors (ATM and MEE) undertook a systematic literature search of a number of 
databases for studies of the effects of ACEI on human AcSDKP levels. Potentially, relevant 
studies were selected on the basis of title and abstract for scrutiny without language restriction. 
The following databases where searched: PubMed, Google Scholar, EMBASE, and the 
Cochrane Library. A combination of the following search terms (including the use of MeSH) was 
used: angiotensin-converting enzyme, angiotensin-converting enzyme inhibitors, human, N-
acetyl-seryl-aspartyl-lysyl-proline, AcSDKP.  The search strategy is outlined in Table 1.  The 
reference lists of identified articles were reviewed.  Authors and experts undertaking research in 
the field of ACEI and AcSDKP were also consulted. Studies selected for review were 
prospective observational studies of the effects of ACEI on human AcSDKP levels.  
 
Table 1.    PUBMED SEARCH STRATEGY (Adapted for use in other databases) 
#1 ("angiotensin converting enzyme inhibitors" OR "ACE inhibitors") 
#2 ("N-acetylseryl-aspartyl-proline level" OR AcSDKP level) 
#3  (#1 AND #2) Filters: Humans 
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Data Extraction and Management 
Data were extracted by two authors (ATM and MEE) using a standardised data extraction form. 
Data were entered into Review Manager 5.1 statistical software for meta-analysis.  Any 
disagreements on eligibility of articles for inclusion were discussed with BMM. 
 
 
Quality Assessment 
All articles included were critically appraised by two authors (ATM and MEE) for methodological 
quality in accordance with the methods of the Cochrane Collaboration (13).  Each included 
article was assessed for risk of bias based on sequence generation, allocation concealment, 
blinding, and incomplete outcome or missing data, where applicable. Heterogeneity between 
studies was assessed using the chi-square test set at a 10% level of significance (13). The 
impact of any statistical heterogeneity was quantified using the I² statistic. If there was an 
acceptable degree of heterogeneity and it was appropriate to pool the data, the Mantel-
Haenszel statistical method and Random Effects Analysis Model were used with the results 
presented in the form of a meta-analysis.  
 
Data Synthesis and Analysis 
Two authors (ATM and MB) reviewed all the relevant articles identified from the search, and 
after scanning the titles, identified those which were for potential inclusion, subject to reading 
the abstracts. The full text of the articles was obtained for final evaluation for inclusion into the 
review according to the pre-specified inclusion criteria.  The PRISMA guideline was used in 
reporting the findings of this review (14). The outcome (i.e., effect of ACEI on AcSDKP level) 
was considered as a continuous variable. The outcome measure was calculated using risk ratios 
and 95% confidence intervals.  Outcomes expressed in ng/ml were converted to pmol/ml by 
dividing the ng/ml value by the molecular weight of AcSDKP (487 Daltons) X10-3. Interquartile 
ranges were converted to standard deviations as per recommended methods (Cochrane 
Handbook). 
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Results 
Seventy-four papers where identified by electronic search of which 55 papers were excluded 
based on title and abstract (Fig. 1). A further 15 papers were excluded following full review of 
the text given that they were animal studies (n=8) or not related to primary outcome (n=7). 
Thus, four studies met with the inclusion criteria (Azizi 1996, Azizi 1997, Azizi 1999, Inoue 
2010). The included studies were conducted in France (Azizi 1996, Azizi 1997, Azizi 1999) and 
Japan (Inoue 2010).  The studies in France included healthy subjects (Azizi 1996), patients with 
hypertension (Azizi 1997) and patients with renal failure (Azizi 1999). The study in Japan (Inoue 
2010) included a combination of healthy patients and those with renal failure.  Included studies 
are described in Table 2.  The reasons for excluding studies, initially considered relevant, are 
provided in Table 3. 
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Figure 1: Flow diagram of search result 
 
Electronic Search of databases 
n=74 
Excluded by title and 
abstract: 
n=55 
Articles screened by full text 
review 
N=19 
Excluded n=15 
Reasons for exclusion 
Animal studies (8) 
Not related to primary 
outcome (7)  
Included studies 
n=4 
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Table 2.  Characteristic of studies included in the review 
Study Id Methods Participants Intervention/Control Outcome 
Azizi 1996 
 
 
 
 
 
Single dose, double- blind 
two-way crossover study 
design  set in Centre d’ 
Investigations Cliniques, 
Hospital Broussais, Paris 
16 Caucasian healthy 
male volunteers, 
age range : 20-35 years 
Intervention:  captopril (50mg) versus 50ml of water 
(n=8). Control = 8 patients received placebo and 50ml 
of water 
Rise in AcSDKP level in blood following ACEI 
(Captopril) 
Azizi 1997 
 
Prospective cohort study 
set at Broussais Hospital, 
Paris 
 
50 white hypertensive 
patients of both sexes 
aged : 18-75 
Varying dosages of ACE-I were used;   
27 patients (21: M, 6: F) on ACEI. Age range: 58+/-12 
years, SBP: 164+/-33 mmHg. 
Control: 23 patients (17: M, 6:F) not on ACEI. Age 
range: 55+/-8 years; SBP:161+/-21 mmHg 
 
Plasma AcSDKP levels elevated in patients on 
ACEI 
Azizi 1999 
 
Observational study set at 
Broussais Clinical 
Investigation Center 
32 patients on the single 
oral dose; 
 
12 patients on the 
multiple oral doses;  
 
 
58 patients with CRF; 
 
40 patients normal renal 
function 
Single oral dose study: 32 patients - 
Captopril (50mg) with 25ml of water 
 
Multiple Oral Dose study:12 patients 
10 : Captopril(50mg) with 25ml of water; 2: placebo with 
25ml of water 
58 patients: 35 on ACEI;  23 not on ACEI 
 
40 patients with normal renal function:19 on ACEI;  21 
not on ACEI 
1. Renal failure was associated with a slight 
increase in plasma AcSDKP levels; 
 
2. AcSDKP levels were increased in patients 
with normal renal function treated with an  
ACEI but only moderate because of ACE was 
intermittently reactivated between doses 
Inoue 2010 
 
Observational study set at 
Meiyo clinic Japan 
41 patients:  7 healthy, 
34 on dialysis. 
 
28 dialysis patients:  10, 
Enalapril;   
18, Trandolapril  
Existing patients on ACEI – no dosages stated. Study focused on relatively simple and highly 
sensitive and specific analytical method for the 
quantitative determination of AcSDKP and 
AcSDKP minor in human plasma samples 
using SPE and LC-MS/MS in the MRM mode 
 
ACEI, angiotensin converting enzyme inhibitor; CRF, chronic renal failure; SBP, systolic blood pressure; LC-MS/MS, liquid  chromatography- tandem mass  spectrometry, SPE, solid  phase extraction, MRM, multiple reaction 
monitoring, AcSDKP minor-synthesised from  thymosin β₁ ₀
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Table 3:  Characteristics of Excluded Studies 
Study  ID Reason for exclusion  
(15) Bogden,1991 Animal study 
(16) Cashman,1994 Animal study 
(17) Comte,1998 Animal study 
(18) Struthers,1999 Not related to primary outcome 
(19) Azizi,2000 Not related to primary outcome 
(20) Azizi,2001 Not related to primary outcome 
(21) Peng,2003 Animal study 
(7) Cavasin,2004 Not related to primary outcome 
(22) Rasoul,2004 Animal study 
(23) Azizi,2006 Units of measurement provided as a ratio (AcSDKP/Creatinine) 
(24) Cavasin,2007 Animal study 
(25) Lin,2013 Animal study 
(26) Liu,2009 Not related to primary outcome 
(27) Wang,2010 Animal study 
(28) Nakagawa,2012 Not related to primary outcome 
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Change in AcSDKP levels in healthy participants  
 
Three studies (106 participants) assessed the change in the levels of AcSDKP following ACE-I 
administration in healthy humans (9,10,29).  Given the high statistical heterogeneity between 
studies (I2 = 81%), a random-effects model was used.  The administration of an ACE-I was 
associated with an increase in AcSDKP levels (mean difference (MD), 5.07 pmol/ml (95% 
confidence intervals (CI) 0.64 to 9.51 pmol/ml).  (Fig. 2).  After exclusion of the trial with a small 
number of participants (Azizi et al., 1996), the effect of ACE-I on AcSDKP levels remained 
significant with a mean difference of 2.62 pmol/ml (95% CI 0.93 to 4.31).   
 
 
 
 
 
 
 
 
Figure 2:  Change in AcSDKP levels in healthy participants. IV; inverse variance 
 
 
Change in AcSDKP levels in participants with renal failure  
 
Two studies with 100 participants assessed the change in AcSDKP level in humans with renal 
failure using ACE-I (29,30).  One study administered Captopril (29), while the second (30) used 
two types of ACE-I namely enalapril and trandolapril.  Administration of an ACE-I was 
associated with a significant increase in AcSDKP levels (MD, 8.94 pmol/ml; 95% CI 2.55 to 
15.33; I2 = 44%)  (Fig.3).    
 
 
  
Figure 3:  Change in AcSDKP levels in participants with renal failure 
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Methodological Quality 
Table 3 shows the risk of bias assessment which included the components of random sequence 
generation, allocation concealment, blinding of participants and personnel, blinding of outcome 
assessment, incomplete data and selective outcome reporting. All these components were 
assessed as being either low risk, high risk or unclear. There were no missing data in any of the 
studies. 
 
Table 3: Risk of Bias Assessment 
 
 
 
Discussion 
 
This study shows that ACEI increase plasma levels of AcSDKP in humans. This effect is 
present in health and disease, and appears to be a class effect of ACEI. These findings are 
consistent with observations of animal models. There were, however, no studies of the impact 
of ACEI in other body tissues such as the pericardium, nor were there studies of the effect of 
higher levels of AcSDKP on tissue fibrosis.  
 
The hypothesis that treatment with ACEI may increase the levels of AcSDKP in patients with 
TB pericarditis that was put forward by Ntsekhe and others is supported by this study (Ntsekhe 
et al 2012). Our findings open the way for experiments to determine whether ACEI can safely 
increase AcSDKP levels in pericardial fluid. However, the hypotensive effect of ACEI may be 
deleterious in patients with haemodynamic instability caused by TB pericarditis. The question of 
the safety of ACEI in TB pericarditis may be examined in prospective studies such as the IMPI 
trial where patients were treated for the clinical syndrome of heart failure(4). 
Study  ID Random 
sequence 
generation 
Allocation 
concealment 
Blinding of 
participants 
and personnel 
Blinding of 
outcome 
assessment 
Incomplete 
outcome 
Data 
Selective 
Outcome 
Reporting 
Azizi 1996 Low risk Unclear Low risk Low risk Low risk Low risk 
Azizi 1997 N/A High risk High risk High risk Low risk Low risk 
Azizi 1999 
 
N/A High risk High risk High risk Low risk Unclear 
Inoue 2010 N/A High risk High risk High risk Unclear Unclear 
N/A; Not applicable 
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The inclusion of four studies with a total of 206 participants from France and Japan may be 
seen as a limitation of this study. It is reassuring however that the direction of effect of ACEI on 
AcSDKP was consistent in this study, and followed the biological expectation. The findings 
therefore have both internal and external validity, and are likely to be of general relevance. 
 
Conclusions 
ACE inhibition elevates AcSDKP levels in human plasma.  These findings provide the rationale 
for further studies being needed so as to allow for the investigation of the effect of ACEI on 
AcSDKP levels in pericardial fluid and impact on the incidence of constriction in tuberculous 
pericarditis. 
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INCLUSION/EXCLUSION AND DATA EXTRACTION 
The effects of ACE-i on human AcSDKP Levels 
 
Study Information 
 
PART I: Eligibility 
 
Study detail 
Eligibility criteria 
(Tick as appropriate) 
Eligibility criterion 
fulfilled 
(Tick as appropriate) 
 Yes                   No                Unclear 
Location 
in text 
Participant 
     Human participants 
 
     Animal models 
                                 
Intervention      ACE inhibitor                                  
Comparator 
     Standard of care 
 
     Placebo 
 
     Nothing 
                                 
First author: 
 
 
Year: 
 
 
Study ID: 
 
 
Study title: 
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DO NOT PROCEED IF EXCLUDED FROM REVIEW 
 
Outcome 
     Change in serum AcSDKP 
level  
                                 
Study design 
     Observational 
 
     Clinical controlled trial 
                                 
 
Study eligibility  (tick as appropriate) 
 INCLUDE   EXCLUDE    UNCLEAR 
 
Reason for exclusion: Reason for uncertainty: 
 
 
Contact author 
Author contact details: 
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PART II: Population and setting 
 
Description 
Location 
in text 
Study population 
description 
(from which participants are 
drawn) 
  
Setting 
(location, social context) 
  
Inclusion criteria  
 
  
Exclusion criteria 
 
  
Method/s of 
recruitment of 
participants 
  
Notes:    
 
 
 
PART III: Methods 
 
Descriptions as stated in report/paper 
Location 
in text 
Aim of study 
  
Design 
( parallel, crossover, cluster) 
  
Assessment Method   
Method of 
Randomisation 
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PART IV: Participants 
 Intervention 
Control Total 
Age range 
   
Sex 
   
Race/Ethnicity   
 
Severity of 
illness 
 
 
 
 
 
Co-morbidities 
 
 
 
 
 
 
Other treatment 
received  
(additional to study 
intervention) 
   
Notes:    
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PART  V: Treatment Arms 
Group name Intervention Contorl Total 
No. randomised to 
group 
(specify whether no. people or 
clusters) 
   
Description Of 
Intervention  
(include sufficient detail for 
replication, e.g. content, dose, 
components) 
   
Duration of treatment 
period 
   
Timing  
(e.g. frequency, duration of each 
episode) 
   
Delivery  
(e.g. mechanism, medium, intensity, 
fidelity) 
   
Providers 
(e.g. no., profession, training, 
ethnicity etc. if relevant) 
   
Co-interventions 
 
 
   
Notes:    
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PART VI: Outcomes 
Primary outcome: change in AcSDKP LEVELS following ACEi administration 
 Description as stated in report/paper 
Location 
in text 
Outcome name   
Time points measured   
Time points reported 
 
  
Outcome definition 
(with diagnostic criteria if relevant) 
  
Person 
measuring/reporting 
 
  
Unit of measurement    
Scales: upper and 
lower limits  
(indicate whether high  or low 
score is good) 
  
Is outcome/tool 
validated? 
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Imputation of missing 
data 
(e.g. assumptions made for ITT 
analysis) 
  
Assumed risk estimate 
(e.g. baseline or population risk 
noted  in background) 
  
Power   
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Secondary outcome: EFFECT OF ACE-I ON BLOOD PRESSURE ON PARTICIPANTS 
 Description as stated in report/paper 
Location 
in text 
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Outcome name   
Time points measured   
Time points reported 
 
  
Outcome definition 
(with diagnostic criteria if relevant) 
  
Unit of measurement    
Is method of 
measurement 
validated? 
                                                                                   
Yes                                               No                                        
Unclear 
 
Notes:    
 
 
 
PART VII: RESULTS 
PRIMARY OUTCOME RESULTS: CHANGE IN Acsdkp levels following acei administration 
    Intervention   Control   Total 
Comparison 
 
   
Outcome 
 
   
Subgroup 
 
   
Results 
Intervention 
Comparison  
µ Variance 
No. 
participant
s µ Variance 
No. 
particip
ants 
 
      
No. missing 
participants and 
reasons 
   
No. participants 
moved from other 
group and reasons 
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Any other results 
reported 
 
  
Time Points 
measured 
  
Time points 
reported 
  
Is measurement 
method validated 
  
Adverse Events)   
Notes:    
 
 
 
 
Description as stated in report/paper 
Location 
in text 
Comparison 
 
  
Outcome 
 
  
Subgroup 
 
  
Post-intervention or 
change from 
baseline? 
  
Results 
Intervention 
Comparison  
µ Variance 
No. 
participant
s µ Variance 
No. 
participant
s 
 
      
No. missing 
participants and 
reasons 
   
No. participants 
moved from other 
group and reasons 
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Any other results 
reported 
 
  
Time points 
reported 
  
Time points 
measured 
  
Is measurement 
method validated 
  
Adverse events    
Notes:   
 
 
PART VIII: Risk of bias assessment 
Domain 
Risk of bias 
Supporting evidence 
 
Location 
in text 
Low 
risk 
Hig
h 
risk 
Unclea
r 
Random sequence 
generation 
(selection bias) 
   
  
Allocation 
concealment 
(selection bias) 
   
  
Blinding of 
participants and 
personnel 
(performance bias) 
   
  
Blinding of outcome 
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(detection bias) 
   
  
Incomplete outcome 
data 
(attrition bias) 
   
  
Selective outcome 
reporting 
(reporting bias) 
   
  
Notes:    
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Have important 
populations been 
excluded from the 
study? 
 (consider disadvantaged 
populations, and possible differences 
in the intervention effect)  
   
Yes No Unclear 
Notes: 
Is the intervention likely 
to be aimed at 
disadvantaged groups? 
(e.g .lower socioeconomic groups) 
   
Yes No Unclear 
Notes: 
Does the study directly 
address the review 
question? 
(any issues of partial or indirect 
applicability) 
   
Yes No Unclear 
Notes: 
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Key conclusions of 
study authors 
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relevant studies 
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required for further 
study information 
 
Notes:   
 
 
 
 
